Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1
Over the next three years, the chosen project, led by Roger Gomis (IRB) in consortium with Aleix Prat (Clínic-IDIBAPS), will study the factors that c1
Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A study promoted by SOLTI and published in Nature Communications describes the tumour biology associated with the activity of the drug patritumab der1
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
On 27 June 2024, a social return event was held at the TV3 facilities, thanking the public for the television marathon devoted to cancer.
The stemTIME project, led by Dr. Silvia Affo from IDIBAPS, investigates how cancer stem cells influence the tumor and immune microenvironment in intr1
The goal of the current campaign is to reach 1,000 hours of cancer research. For each book read, 10 minutes of research, and for every six books, one1
